

Please amend the application as follows:

In the Claims

Please cancel Claims 221-245 and 267-291. Please amend Claims 151-157, 163-169, 175-179, 185-188, 194-198, 204-207, 213, 217, 246-250, 253, 257-260, 263, 292, 296, 300 and 303. Please add new Claims 308-356. Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i - ix).

- 61
151. (Amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.
 152. (Amended) The antibody or antigen-binding fragment of Claim 151, wherein said C-C chemokine receptor 3 protein has binding specificity for RANTES.
 153. (Amended) The antibody or antigen-binding fragment of Claim 151, wherein said C-C chemokine receptor 3 protein has binding specificity for MCP-3.
 154. (Amended) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
 155. (Amended) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
 156. (Amended) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11

(ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

61 157. (Amended) The antibody or antigen-binding fragment of Claim 151, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

163. (Amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.

164. (Amended) The antibody or antigen-binding fragment of Claim 163, wherein said C-C chemokine receptor 3 protein has binding specificity for RANTES.

165. (Amended) The antibody or antigen-binding fragment of Claim 163, wherein said C-C chemokine receptor 3 protein has binding specificity for MCP-3.

62 166. (Amended) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.

167. (Amended) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

168. (Amended) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

62 169. (Amended) The antibody or antigen-binding fragment of Claim 163, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

175. (Amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for eotaxin.

176. (Amended) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.

177. (Amended) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

63 178. (Amended) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

179. (Amended) The antibody or antigen-binding fragment of Claim 175, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

185. (Amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for eotaxin.

186. (Amended) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.

64 187. (Amended) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.

188. (Amended) The antibody or antigen-binding fragment of Claim 185, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

194. (Amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

65 195. (Amended) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.

196. (Amended) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

197. (Amended) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11

(ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

65

198. (Amended) The antibody or antigen-binding fragment of Claim 194, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
-

204. (Amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

205. (Amended) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.

66

206. (Amended) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.

207. (Amended) The antibody or antigen-binding fragment of Claim 204, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
-

67

213. (Amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6.
-

68 217. (Amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:4.

246. (Amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO: 1 or the complement of SEQ ID NO:5 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C, and has binding specificity for eotaxin.

69 247. (Amended) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.

248. (Amended) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

249. (Amended) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

250. (Amended) The antibody or antigen-binding fragment of Claim 246, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

610
Ent #2

253. (Amended) The antibody or antigen-binding fragment of Claim 246, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.

Ent #3

611

257. (Amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C, and has binding specificity for eotaxin.

258. (Amended) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.

259. (Amended) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.

260. (Amended) The antibody or antigen-binding fragment of Claim 257, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

263. (Amended) The antibody or antigen-binding fragment of Claim 257, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.

292. (Amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:1 or SEQ ID NO:5.

296. (Amended) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:3.

300. (Amended) Antibody 7B11 (ATCC Accession No. HB-12195) or an antigen-binding fragment thereof.

303. (Amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3, wherein said antibody or antigen-binding fragment comprises the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11 (ATCC Accession No. HB-12195).

308. (New) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein that is expressed on the surface of a cell, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with

SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.

309. (New) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
310. (New) The antibody or antigen-binding fragment of Claim 309, wherein said ligand is selected from the group consisting of RANTES and MCP-3.
311. (New) The antibody or antigen-binding fragment of Claim 308, wherein said C-C chemokine receptor 3 protein comprises SEQ ID NO:2.
- 617 312. (New) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
313. (New) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
314. (New) The antibody or antigen-binding fragment of Claim 308, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
315. (New) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.

316. (New) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
317. (New) A composition comprising the antibody or antigen-binding fragment of Claim 308 and a physiologically acceptable vehicle or carrier.
318. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 308.
319. (New) The isolated cell of Claim 318, wherein said isolated cell is a hybridoma.
- 617 320. (New) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein that is expressed on the surface of a cell, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for eotaxin.
321. (New) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
322. (New) The antibody or antigen-binding fragment of Claim 321, wherein said ligand is selected from the group consisting of RANTES, MCP-3 and eotaxin.
323. (New) The antibody or antigen-binding fragment of Claim 320, wherein said C-C chemokine receptor 3 protein comprises SEQ ID NO:2.
324. (New) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC

Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

325. (New) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

326. (New) The antibody or antigen-binding fragment of Claim 320, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

327. (New) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.

617 328. (New) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

329. (New) A composition comprising the antibody or antigen-binding fragment of Claim 320 and a physiologically acceptable vehicle or carrier.

330. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 320.

331. (New) The isolated cell of Claim 330, wherein said isolated cell is a hybridoma.

332. (New) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein that is expressed on the surface of a cell, wherein said

C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

333. (New) The antibody or antigen-binding fragment of Claim 332, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
334. (New) The antibody or antigen-binding fragment of Claim 333, wherein said ligand is selected from the group consisting of RANTES, MCP-3, eotaxin, MCP-2 and MCP-4.
335. (New) The antibody or antigen-binding fragment of Claim 332, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
- 617 336. (New) The antibody or antigen-binding fragment of Claim 332, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
337. (New) The antibody or antigen-binding fragment of Claim 332, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
338. (New) A composition comprising the antibody or antigen-binding fragment of Claim 332 and a physiologically acceptable vehicle or carrier.
339. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 332.
340. (New) The isolated cell of Claim 339, wherein said isolated cell is a hybridoma.

- 2-157
341. (New) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein that is expressed on the surface of a cell, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO: 1 or the complement of SEQ ID NO:5 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C, and has binding specificity for eotaxin.
342. (New) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
- 617
343. (New) The antibody or antigen-binding fragment of Claim 342, wherein said ligand is selected from the group consisting of RANTES, MCP-3 and eotaxin.
344. (New) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
345. (New) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
- 2-167
346. (New) The antibody or antigen-binding fragment of Claim 341, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

347. (New) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
348. (New) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
349. (New) The antibody or antigen-binding fragment of Claim 341, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.
350. (New) A composition comprising the antibody or antigen-binding fragment of Claim 341 and a physiologically acceptable vehicle or carrier.
351. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 341.
352. (New) The isolated cell of Claim 351, wherein said isolated cell is a hybridoma.
353. (New) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein that is expressed on the surface of a cell, wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6.

Sub #7
617